RO

Laboratorios Farmaceuticos ROVI SAMAD Laboratorios Farmaceuticos Stock Report

Last reporting period 30 Jun, 2024

Updated 18 Oct, 2024

Last price

Market cap $B

4.095

Middle

Exchange

XMAD - Bolsa de Madrid

ROVI.MC Stock Analysis

RO

Uncovered

Laboratorios Farmaceuticos ROVI SA is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

78/100

Moderate score

Market cap $B

4.095

Dividend yield

1.29 %

Shares outstanding

53.372 B

Laboratorios Farmaceuticos ROVI SA (ROVI) is a Spain-based company principally engaged in the pharmaceutical industry. The Company’s main activities include the development and commercialization, nationwide and abroad, of medicines and drugs. Its products are structured into three fields: Diagnostic, which offers contrast mediums for use in magnetic resonance, ultrasound and X-ray diagnostics; Prescription, which distributes medicines under such brands as Hibor, Osseor, Hepadren, Pneumovax-23, Glufan, Corlentor, Exxiv, Calcio y Vitamina D3 Rovi and Absorcol, among others; and Over The Counter (OTC), which comprises the Perspirex, Enerzona, Dentimelo and ColdPack brands. The Company owns such fully consolidated subsidiaries as Gineladius SL, Frosst Iberica SA, Rovi Contract Manufacturing SL and Bertex Pharma GmbH, among others.

View Section: Eyestock Rating